Oramed is one of 60 Companies Selected to Participate at the "Facing
Tomorrow" Conference Marking the Country's 60th Birthday
JERUSALEM, Israel, May 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP), a developer of oral delivery systems, has been selected for the first annual Presidential conference, "Facing Tomorrow," as one of the 60 "enterprises of tomorrow" representing the future face of Israel. The monumental event is being held to mark the country's sixtieth birthday.
Additionally, Oramed was one of six companies chosen to be featured in a video presentation at the conference's opening event. The conference will be attended by global political and business leaders, including Israeli Prime Minister Ehud Olmert, President George W. Bush and Google founder Sergey Brin.
"The selection of Oramed as one of the companies to change the face of tomorrow is a great honor," said Nadav Kidron, CEO of Oramed Pharmaceuticals. "Being chosen for the conference illustrates the potential of our technology to make a significant difference for millions of diabetics around the world."
The conference will be held May 13-15 at the Jerusalem International Convention Center.
For more information on the conference, please visit the conference's website at: http://www.presidentconf.org.il/en/
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is an Israeli-based company focused on the development of oral delivery solutions based on proprietary technology. Oramed is currently developing an orally ingestible insulin capsule for the treatment of diabetes. The oral administration of insulin is more physiological than the current delivery method, mimicking the natural path of insulin throughout the body. The company is also pursuing the development of oral delivery solutions for drugs and vaccines presently delivered via injection.
For more information, please visit our website at: http://www.oramed.com
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the
risks and uncertainties related to the progress, timing, cost, and results
of clinical trials and product development programs; difficulties or delays
in obtaining regulatory approval for our product candidates; competition
from other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its research,
development and commercialization activities. Please refer to the company's
filings with the Securities and Exchange Commission for a comprehensive
list of risk factors that could cause actual results, performance or
achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no
obligation to update or revise any forward-looking statements.
Company and Investor Relation Contacts:
Ruder Finn Israel for Oramed
|SOURCE Oramed Pharmaceticals|
Copyright©2008 PR Newswire.
All rights reserved